Sector News

Sanofi eyes big Cambridge, Massachusetts, expansion for Genzyme business

October 16, 2018
Life sciences

Many biopharma companies are cutting costs and slimming down—including Sanofi itself—but not in its Genzyme business.

The French pharma is looking to expand its rare disease footprint in Cambridge, Massachusetts, with 400,000 square feet of office and lab space that could house about 2,000 employees, The Boston Globe reported, citing real estate sources familiar with Sanofi’s search.

Moving thousands of jobs into Cambridge from the Greater Boston area would give the thriving biotech hub yet another boost and bring more Sanofi Genzyme workers into an innovation hotbed full of potential partners and potential hires down the road.

Sanofi confirmed that it’s eyeing its Boston-area facilities for some changes. “The Greater Boston area is a key hub for Sanofi, where we currently have more than 15 separate offices, labs and manufacturing sites. In light of this, the company is developing a long-term real estate plan for the region,” a Sanofi spokesperson said in a statement to FiercePharma, adding that nothing has been finalized yet.

Genzyme tallies about 5,000 employees in Massachusetts, including its Cambridge headquarters. The company would like to bring at least some of those dispersed operations together, and will probably move some jobs from its Framingham, Massachusetts, manufacturing facility, while still have some room for future growth, says The Boston Globe.

“They need 400,000, maybe eventually up to 800,000 square feet,” Aaron Jodka, research director at real estate firm Colliers International, told the newspaper. “We’ve been hearing them attached to pretty much any big block of space in Cambridge.”

Fresh off its $11.6 billion acquisition of Waltham, Massachusetts-based Biogen spun-off, hemophilia drug developer Bioverativ, Sanofi has moved Genzyme from its old HQ to a brand new, 275,000-square-foot place at 50 Binney St., still in Kendall Square—a move it had planned for years.

Shire had previously planned to take over the lease of the old Genzyme campus, which is adjacent to Shire’s own operations, with the original plan to make an innovation hub of its own. But that plan has been complicated by the Takeda buyout as the Japanese pharma will likely look for ways to consolidate instead. According to the Boston Business Journal last month, Shire has backed out of a deal to lease the place.

Per the Globe, Sanofi is evaluating a space close to Kendall Square at Cambridge Crossing, as well as buildings by MIT and Harvard, and it’s not year clear whether a deal has been reached. But several brokers who talked to the newspaper said the Cambridge Crossing site—close to Kendall Square—seems like the best option because it has large buildings with room to grow.

Under pressure from a declining diabetes business, Sanofi is going through a five-year restructuring unveiled in 2015 by CEO Oliver Brandicourt to help grow its Genzyme business and offset losses elsewhere. In December 2016, it announced a plan to cut 20% of its U.S. diabetes sales force back, and in January of this year, the company laid off 400 U.S. diabetes and cardiovascular salespeople.

And as its diabetes and CV franchise continues to plummet, Genzyme has come to Sanofi’s rescue, with special thanks to eczema recent launch Dupixent, whose €176 million ($204 million) in the second quarter of 2018 came 12% above analysts’ projections. Awaiting a key FDA decision in asthma soon, the drug is expected to grow to nearly $8.1 billion by 2024, according to pharmaceutical data intelligence firm Evaluate Pharma.

Taking into account its recent purchases of Bioverativ and Ablynx, Genzyme could use some extra pairs of hands to carry its growth.

The Greater Boston area has always been a hot biotech hub. Takeda just announced a plan to move its U.S. HQ from Chicago area to the greater Boston area, so that it could be closer to Shire. The Japanese pharma already has a strong presence in Cambridge with its previous acquisitions of Millennium and Ariad.

And in June, another French pharma, Ipsen, said it is moving its U.S. base from New Jersey to Kendall Square. As for the Cambridge Crossing campus, it recently welcomed Philips Healthcare’s North American headquarters.

By Angus Liu

Source: Fierce Pharma

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach